title: Molecular cytogenetic monitoring from CD34+ peripheral blood cells in myelodysplastic syndromes: first results from a prospective multicenter German diagnostic study.
abstract: The gold standard of cytogenetic analysis in myelodysplastic syndromes (MDS) is conventional chromosome banding (CCB) analysis of bone marrow (BM) metaphases. Most aberrations can also be detected by fluorescence-in situ-hybridization (FISH). For this prospective multicenter German diagnostic study (www.clinicaltrials.gov: #NCT01355913) 360 patients, as yet, were followed up to 3 years by sequential FISH analyses of immunomagnetically enriched CD34+ peripheral blood (PB) cells using comprehensive FISH probe panels, resulting in a total number of 19,516 FISH analyses. We demonstrate that CD34+ PB FISH correlates significantly with CCB analysis and represents a feasible method for a reliable non-invasive cytogenetic monitoring from PB.
authors.affiliation: Department of Hematology and Oncology, University of Goettingen, Germany. friederike.braulke@med.uni-goettingen.de
authors.forename: Friederike
authors.initials: F
authors.lastname: Braulke
authors.forename: Klaus
authors.initials: K
authors.lastname: Jung
authors.forename: Julie
authors.initials: J
authors.lastname: Schanz
authors.forename: Katharina
authors.initials: K
authors.lastname: Götze
authors.forename: Catharina
authors.initials: C
authors.lastname: Müller-Thomas
authors.forename: Uwe
authors.initials: U
authors.lastname: Platzbecker
authors.forename: Ulrich
authors.initials: U
authors.lastname: Germing
authors.forename: Tim H
authors.initials: TH
authors.lastname: Brümmendorf
authors.forename: Gesine
authors.initials: G
authors.lastname: Bug
authors.forename: Oliver
authors.initials: O
authors.lastname: Ottmann
authors.forename: Aristoteles A N
authors.initials: AA
authors.lastname: Giagounidis
authors.forename: Michael
authors.initials: M
authors.lastname: Stadler
authors.forename: Wolf-Karsten
authors.initials: WK
authors.lastname: Hofmann
authors.forename: Philippe
authors.initials: P
authors.lastname: Schafhausen
authors.forename: Michael
authors.initials: M
authors.lastname: Lübbert
authors.forename: Richard F
authors.initials: RF
authors.lastname: Schlenk
authors.forename: Igor W
authors.initials: IW
authors.lastname: Blau
authors.forename: Christina
authors.initials: C
authors.lastname: Ganster
authors.forename: Sebastian
authors.initials: S
authors.lastname: Pfeiffer
authors.forename: Katayoon
authors.initials: K
authors.lastname: Shirneshan
authors.forename: Michael
authors.initials: M
authors.lastname: Metz
authors.forename: Sven
authors.initials: S
authors.lastname: Detken
authors.forename: Jörg
authors.initials: J
authors.lastname: Seraphin
authors.forename: Kathleen
authors.initials: K
authors.lastname: Jentsch-Ullrich
authors.forename: Angelika
authors.initials: A
authors.lastname: Böhme
authors.forename: Burkhard
authors.initials: B
authors.lastname: Schmidt
authors.forename: Lorenz
authors.initials: L
authors.lastname: Trümper
authors.forename: Detlef
authors.initials: D
authors.lastname: Haase
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018952:Antigens, CD34 / Q000097:blood / Q000378:metabolism*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001374:Azacitidine / Q000008:administration & dosage / Q000627:therapeutic use; D002869:Chromosome Aberrations / Q000187:drug effects; D002871:Chromosome Banding / Q000379:methods*; D005260:Female; D005500:Follow-Up Studies; D005858:Germany; D006801:Humans; D017404:In Situ Hybridization, Fluorescence / Q000379:methods*; D000077269:Lenalidomide; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000097:blood / Q000188:drug therapy / Q000235:genetics*; D011446:Prospective Studies; D013792:Thalidomide / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D018952:Antigens, CD34; D013792:Thalidomide; D000077269:Lenalidomide; D001374:Azacitidine